Advanced search
Publication Cover
OncoTargets and Therapy Volume 14, 2021 - Issue
Submit an article Journal homepage
112
Views
8
CrossRef citations to date
0
Altmetric
Case Report

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report

Rengui Zhou1 Department of Hematology and Oncology, The 904 Hospital of the PLA (Chinese People’s Liberation Army), Wuxi, People’s Republic of China
,
Lei Song1 Department of Hematology and Oncology, The 904 Hospital of the PLA (Chinese People’s Liberation Army), Wuxi, People’s Republic of China
,
Wenwen Zhang1 Department of Hematology and Oncology, The 904 Hospital of the PLA (Chinese People’s Liberation Army), Wuxi, People’s Republic of China
,
Lin Shao2 Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China
,
Xi Li2 Burning Rock Biotech, Guangzhou, Guangdong, People’s Republic of China
&
Xiangyong Li1 Department of Hematology and Oncology, The 904 Hospital of the PLA (Chinese People’s Liberation Army), Wuxi, People’s Republic of ChinaCorrespondence[email protected]
Pages 2847-2851 | Published online: 28 Apr 2021

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Danilo Rocco, Luigi Della Gravara, Paolo Maione, Giovanni Palazzolo & Cesare Gridelli. (2022) Identification of drug combinations for lung cancer patients whose tumors are unresponsive to targeted therapy: clinical bases and future directions. Expert Review of Precision Medicine and Drug Development 7:1, pages 29-38.
Read now

Articles from other publishers (7)

Satyam Singh, Sushabhan Sadhukhan & Avinash Sonawane. (2023) 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1878:6, pages 188967.
Crossref
Mingzhao Wang, Jun Zhao, Tong Chen, Xingsheng Hu, Lin Wang, Yuankai Shi & Yutao Liu. (2023) Efficacy and safety of osimertinib plus anlotinib in advanced non‐small‐cell lung cancer patients after drug resistance. Thoracic Cancer 14:10, pages 873-880.
Crossref
Kai Fu, Fachao Xie, Fang Wang & Liwu Fu. (2022) Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology & Oncology 15:1.
Crossref
Ruizhu Sun, Zhansheng Hou, Yankui Zhang & Bo Jiang. (2022) Drug resistance mechanisms and progress in the treatment of EGFR‑mutated lung adenocarcinoma (Review). Oncology Letters 24:5.
Crossref
Bin Zhou, Qiang Gong, Ben Li, Hai‐Ling Qie, Wei Li, Hong‐Tao Jiang & He‐Fei Li. (2022) Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M‐positive NSCLC: A retrospective study. Journal of Clinical Pharmacy and Therapeutics 47:5, pages 643-651.
Crossref
Yue Zeng, Danlei Yu, Wentao Tian & Fang Wu. (2022) Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer. Current Opinion in Oncology 34:1, pages 54-65.
Crossref
. (2021) Cisplatin/gefitinib/osimertinib. Reactions Weekly 1867:1, pages 125-125.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.